the product in the database has an inactive status
indications:
Hypertension. Stable angina and angina pectoris caused by vasoconstriction (Prinzmetal's form).
Composition:
One time-delayed capsule contains 90 mg or 120 mg diltiazem hydrochloride. The product contains sucrose.
Action:
A selective Calcium channel antagonist that acts directly on the myocardium. The mechanism of action is to block the influx of calcium ions into the cells, mainly within the myocardium and smooth muscle of blood vessels. Diltiazem lowers the tone of the peripheral and coronary vascular smooth muscles and slows the frequency of heart contractions, which results in lowering blood pressure, reducing the oxygen consumption in the heart muscle and improving the heart's oxygen supply. It releases the guidance primarily in the atrioventricular node, exerting very little influence on the sinus node. It is well absorbed from the gastrointestinal tract, reaching the maximum concentration in the blood after 3-5 hours of administration. Plasma proteins are 80% bound. Diltiazem is extensively metabolised in the liver with the participation of cytochrome P450 (which is the cause of a clear first-pass effect). It is excreted from the body with bile and urine, with only up to 4% excreted unchanged.
Contraindications:
Hypersensitivity to diltiazem or other components of the preparation. The syndrome of sick sinus in patients with a pacemaker. Atrioventricular block (AV) IIst. and third century, except for patients with a pacemaker. Symptomatic heart failure. Rare tachycardia (bradycardia) <50 bpm / min. Hypotension (blood systolic pressure <90 mmHg). Concomitant use of dantrolene in the form of an intravenous infusion. Shock. acute myocardial infarction with complications (bradycardia, significant hypotension, left ventricular failure). Use in women of childbearing potential not using contraception. Atrial fibrillation / flutter and coexisting Wolff-Parkinson-White syndrome (increased risk of subsequent ventricular fibrillation). Left ventricular failure with stasis.
Precautions:
Use with caution in patients with impaired hepatic or renal function, in the elderly, in patients with atrioventricular block Ist. or prolonged PR interval (the drug prolongs the refractory period of the atrioventricular node without significantly extending the sinus rhythm recovery time unless the patient has a sinus syndrome, it may in rare cases cause tachycardia, especially in patients with sinus syndrome, and atrioventricular block II or III), with mild tachycardia or left ventricular dysfunction. Patients taking diltiazem may need to change the dosage of antidiabetic agents. Due to the sucrose content, the drug should not be used in patients with rare inherited disorders associated with fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency. The drug is not recommended for use in children.
Pregnancy and lactation:
The preparation is contraindicated during pregnancy (may cause serious birth defects). Diltiazem is excreted in human milk, therefore it should not be used in nursing mothers; if the use of the drug is necessary, breastfeeding should be discontinued.
Side effects:
Common: headache and dizziness, edema, atrioventricular block Ist, sinus tachycardia (a dose dependent symptom), nausea, rash, sudden facial blows. Frequency not known: memory impairment, gait disturbances, paresthesia, drowsiness, tremors, fainting; arrhythmia, atrioventricular block II or III, congestive heart failure, coronary pain, palpitations; constipation, diarrhea, indigestion, vomiting, gingivitis, gingival hypertrophy; ecchymosis, urticaria, pruritus, hypersensitivity to light, Stevens-Johnson syndrome, cutaneous allergic reactions (including erythema multiforme); hypotension, vasculitis; depression, personality disorders, hallucinations, increased nervous excitability,insomnia; ringing and tinnitus; increased creatinine kinase activity in blood serum, increase in blood Glucose, slight increase in aspartic aminotransferase (Asp AT), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) or alkaline phosphatase, weight loss; amblyopia, paralysis; shortness of breath, nosebleeds, reduction of nasal patency caused by nasal mucosal edema; urination at night, polyuria; muscle pain and osteoarticular pain; difficulties in the sexual sphere, gynecomastia; lymphadenopathy, eosinophilia, thrombocytopenia; loss of appetite. Reactions such as hypersensitivity to light, ecchymosis, urticaria, pruritus and allergic skin reactions (including erythema multiforme) may be transient and recede despite continuing to take the medicine; if they do not disappear, the preparation should be discontinued.
Dosage:
Orally. Adults: The starting dose is 90 mg 2 times a day; depending on the therapeutic effect and the tolerance of the preparation, the dose may be gradually increased to a dose of 360 mg daily, administered in two equal doses. Elderly patients or patients with impaired hepatic and renal function: the starting dose is 60 mg diltiazem hydrochloride 2 times daily, then the dose should be gradually increased until the desired therapeutic effect is achieved. Do not increase the dose if your heart rate falls below 50 beats per minute. The capsules should not be sucked or chewed.
(C)
